COLL vs TDOC: Which Stock Is the Better Buy?
Collegium Pharmaceutical, Inc. and Teladoc Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — COLL vs TDOC, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Collegium Pharmaceutical, Inc. (COLL) | Teladoc Health, Inc. (TDOC) | |
|---|---|---|
| Market cap | $1.1B | $1.3B |
| Revenue (latest FY) | $780.57M | $2.53B |
| Net income (latest FY) | $62.87M | $-200.32M |
| Revenue growth (5y CAGR) | 20.3% | 18.3% |
| Net margin | 8.1% | -7.9% |
| Return on equity | 20.8% | -14.5% |
| P/E ratio | 16.8 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 0 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full COLL vs TDOC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open COLL's full financials → Open TDOC's full financials →More comparisons
Frequently asked questions
Which is bigger, COLL or TDOC?
Teladoc Health, Inc. is larger by market capitalization — $1.3B versus $1.1B.
Which grows faster, COLL or TDOC?
Over the last five fiscal years, Collegium Pharmaceutical, Inc. grew revenue faster — 20.3%/yr versus 18.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.